Lantern Pharma Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 13.05K shares.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 0.00 shares.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 0.00 shares.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 13.05K shares.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 32.54K shares, a 176.17% increase from fiscal 2021.
- Lantern Pharma Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 11.78K shares, a 76.65% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 13.05K shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 13.05K shares 10-Q · filed 2025-11-12 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 0.00 shares 10-K · filed 2026-03-30 |
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-12 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | 32.54K shares 10-K · filed 2024-03-18 |
| 2021-12-31 | 11.78K shares 10-K · filed 2023-03-20 | |
| 2020-12-31 | 50.46K shares 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |